Evidence map›Paper›PMID 42274213›Full record

ArticleJournal of virology2026

A newly developed eGFP-traceable recombinant rhesus lymphocryptovirus, a tool to study viral infection and replication

Erasmus N Kotey, Preeti Sharma, Esther Rodriguez, Jean Patrick Gonzalez-Dahua, Brenda A Tello, Ivana G Reidel, Gabriela M Escalante, Yuqi Zhao, Xiwei Wu, Rodney P Kincaid and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Erasmus N KoteyDepartment of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.
Preeti SharmaDepartment of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.
Esther RodriguezDepartment of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.
Jean Patrick Gonzalez-DahuaIrell & Manella Graduate School of Biological Sciences of City of Hope, Duarte, California, USA.
Brenda A TelloDepartment of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.
Ivana G ReidelDepartment of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.ORCID 0000-0001-8897-4421
Gabriela M EscalanteDepartment of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.ORCID 0000-0003-3182-1947
Yuqi ZhaoDepartment of Integrative Genomics and Bioinformatics, Beckman Research Institute of City of Hope, Duarte, California, USA.
Xiwei WuDepartment of Integrative Genomics and Bioinformatics, Beckman Research Institute of City of Hope, Duarte, California, USA.
Rodney P KincaidVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.
Yan ChenVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.
Rebecca L SkalskyVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, USA.ORCID 0000-0003-2967-9478
Lorraine Z Mutsvunguma *Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.
Javier Gordon Ogembo *Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California, USA.ORCID 0000-0001-6949-8693

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Phase 2 Enhancement of Outdoor Group Housing for U42 SPF 9 Rhesus MacaquesU42OD023038 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI RUDOLF Paul BOHM, Lauren Drew Martin · 2016 to 2026
$21.9M
Unmasking the roles of viral glycoproteins in oral transmission of KSHVR01CA264911 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI OGEMBO, JAVIER GORDON · 2021 to 2025
$4.8M
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV InfectionR01AI151013 · NIAID · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI OGEMBO, JAVIER GORDON · 2021 to 2025
$4.3M
microRNA Regulation of Gamma-herpesvirus Latency and ReactivationR01AI143620 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SKALSKY, REBECCA L · 2019 to 2023
$2.5M
Characterizing single cell states of activated and transformed B cells in rhesus macaque modelsR21AI171354 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SKALSKY, REBECCA L · 2023 to 2024
$434k
Beckman Research Institute, City of Hope Excellence AwardNCI NIH HHS P30 CA033572NCI NIH HHS R01 CA264911NIAID NIH HHS R01 AI143620NIAID NIH HHS R01 AI151013NIAID NIH HHS R21 AI171354NIH HHS R01AI143620NIH HHS R01AI151013NIH HHS R01CA264911NIH HHS R21AI171354NIH HHS U42 OD023038
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is implicated in multiple epithelial and lymphoid malignancies worldwide; however, no licensed prophylactic vaccine exists, partly due to the lack of an adequate preclinical animal model to test candidate vaccines. Rhesus lymphocryptovirus (rhLCV) faithfully recapitulates EBV infection, persistence, and pathogenesis in rhesus macaques, offering an invaluable surrogate model. While recombinant EBV expressing enhanced green fluorescent protein (eGFP) enables swift identification of infected cells IMPORTANCE: Epstein-Barr virus (EBV) infection is associated with various epithelial and lymphoid diseases. The absence of a suitable animal study model for EBV infection has hindered mechanistic studies of pathogenesis and preclinical testing of vaccines and EBV‑targeted therapies. Rhesus lymphocryptovirus (rhLCV), an EBV homolog, accurately recapitulates EBV infection and pathogenesis in rhesus macaques, offering a promising EBV surrogate model. In this study, we engineered a stable recombinant rhLCV expressing enhanced green fluorescent protein (eGFP), rhLCV.eGFP, for easy identification of infected or transformed cells

Indexed as

Green Fluorescent ProteinsHerpesviridae InfectionsLymphocryptovirusViral Matrix ProteinsVirus InternalizationVirus ReplicationAnimalsB-LymphocytesCell LineChromosomes, Artificial, BacterialHerpesvirus 4, HumanHumansLeukocytes, MononuclearMacaca mulattaenhanced green fluorescent proteinGreen Fluorescent ProteinsViral Matrix Proteinsenhanced green fluorescent proteinEpstein-Barr virusgp350host rangemonoclonal antibodiesprimatesrecombinant technologyrhesus lymphocryptovirus

Identifiers

PMID42274213
PMCPMC13386976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.